immunotherapy

Nivolumab + relatlimab

FDA-approved U.S. melanoma context exists for unresectable or metastatic melanoma. Country-by-country access still needs mapping.

Plain-English summary

This combines two immune checkpoint targets: PD-1 and LAG-3. It belongs in immunotherapy conversations and should not be confused with MEK-targeted therapy.

What the sources say

• FDA/NCI sources describe nivolumab plus relatlimab as an approved melanoma drug combination in the source-cited U.S. context.
• The combination is not mutation-specific in the same way BRAF/MEK targeted therapy is.
• It can come up in advanced melanoma discussions, but sequencing after prior PD-1 therapy needs oncology-team clarification.

When this commonly comes up

• Unresectable or metastatic melanoma is being discussed.
• The team is comparing checkpoint inhibitor approaches.
• A family hears both PD-1 and another immune checkpoint name and needs to separate mechanisms.

What this does not mean

• It does not mean MEK inhibition is involved.
• It does not mean it is available or reimbursed in every country.
• It does not automatically answer whether nivolumab plus ipilimumab, PD-1 alone, targeted therapy, TIL, or trials are part of the same conversation.

Important cautions

• Ask whether this is being discussed before or after prior PD-1 therapy.
• Ask how the team compares immune-related risk across checkpoint combinations.
• Do not infer country access from a U.S. approval page.

Questions to ask

• Is this being considered as first-line advanced melanoma immunotherapy or after prior treatment?
• How is this different from nivolumab plus ipilimumab?
• What immune-related side effects are most important to discuss before treatment starts?